India's Strides says gets FDA nod for plant in Italy
Sept 18 (Reuters) - India's Strides Arcolab Ltd said on Wednesday it had received the U.S. Food and Drug Administration's approval for a plant in Italy, helping it foray into the semi-solid market in the United States.
Strides expects its first semi-solid product to be commercialised by the first quarter of next year, it said in a statement. The product will be marketed by one of the top 10 generic companies in the U.S. market.
It did not name the company.
The Strides facility in Milan makes liquids, semi-solids, ointments and creams.
- Pennsylvania newlyweds "just wanted to murder someone together:" police
- WTO overcomes last minute hitch to reach its first global trade deal
- U.S. freeze shows no sign of weekend melt after deadly storm
- Colorado baker discriminated by denying gay couple wedding cake: judge
- North Korea frees U.S. Korean War veteran after seven weeks |